Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of VX-440 alone and with VX-661/ivacaftor in healthy adults
NL-OMON43882Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (7 arms), sponsored by Vertex Pharmaceuticals. Started Nov 2015; status: active, not recruiting.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON43882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43882.